依药物类别、治疗类型和给药途径分類的开放性青光眼药物市场－2025-2032年全球预测

预计到 2032 年，开放性青光眼药物市场规模将达到 187.3 亿美元，复合年增长率为 9.06%。

这是一本简明权威的说明，介绍了不断变化的治疗格局、未满足的需求以及影响开角型青光眼治疗的战略要务。

开放性青光眼仍然是全球不可逆性视力丧失的主要原因，药物研发也在不断发展，以满足尚未满足的临床需求并适应技术进步。近年来，该领域的研究方法已从单纯关注眼压转向多方面策略，这些策略涵盖神经保护、患者依从性和联合治疗。这拓宽了临床医生和支付方在将新药和给药方法应用于临床实践时所评估的证据基础。

新型作用机制的引入、持续给药系统的进步以及对真实世界疗效的日益关注，共同重塑了临床预期和商业模式。因此，製药、生物技术和医疗设备行业的相关人员正在重新评估其市场推广计划、证据生成策略和伙伴关係。本导言重点在于将定义近期治疗格局的变革性转变、监管环境和交易动态、市场区隔细微差别、区域性考量以及策略行动。

机制创新、先进的给药技术以及不断变化的支付方期望如何从根本上改变开放性青光眼的治疗策略和应用

在科学、临床和商业性力量的共同推动下，开放性青光眼的治疗模式正在经历一场变革。机制创新，特别是Rho激酶抑制剂和其他标靶海绵窦房结流出药物的出现，正在挑战传统治疗类别的长期主导地位，并亟需进行直接的疗效比较评估。同时，药物製剂和给药方式的改进，包括缓释性植入和不含防腐剂的局部用药，正在重塑患者的用药依从性和临床实践。

同时，支付方的期望和监管路径也在不断演变，这促使人们更加重视可靠的真实世界证据和卫生经济学评估。诊断技术的创新，例如增强型影像和家庭监测技术，使得早期发现疾病和更个人化的治疗调整成为可能。研发开发平臺优先考虑那些已证实具有持久性和耐受性优势的药物，商业模式强调病患支援和依从性解决方案，而製药和医疗设备製造商之间为提供整合式医疗解决方案而开展的合作也日益普遍。

2025年关税主导的供应链转变及其对维持治疗药物可近性、连续性和商业性发展势头的战略应对措施的实际影响

2025年新关税的实施将为依赖全球采购的零件和原料药的治疗药物和医疗设备带来额外的商业性复杂性。更高的进口关税可能会增加原材料和成品的到岸成本，迫使采购团队重新评估其供应商组合，并考虑双重采购和本地化策略，以维持利润率和供应的连续性。为此，一些製造商正在加速推动近岸外包和製造外包合作，以降低关税波动带来的风险。

关税不仅影响直接成本，还会影响策略时间表和产品上市顺序。企业可能会调整其供应链布局，优先选择贸易摩擦较小的市场，或保护关键生产线免受关税相关干扰。在这种环境下，长期供应协议和价格调整条款等合约保护措施的重要性也日益凸显。从临床角度来看，关税可能透过提高药品标价或限制某些进口製剂的供应，间接影响患者的用药，因此需要扩大患者援助计画并进行灵活的报销谈判。总而言之，关税情势凸显了製定动态商业策略的必要性，这些策略应整合贸易风险评估、供应链韧性和积极的相关人员参与。

基于药物类别、治疗类型和给药途径的细分证据优先事项和商业化途径，塑造了治疗差异化。

对细分市场的深入理解对于根据药物类别、治疗类型和给药途径对资产进行定位，以及确定临床和商业投资的优先顺序至关重要。在药物类别方面，需要考虑的包括α促效剂、 β阻断剂、碳酸酐酶抑制剂、复方製剂、前列腺素类似物和Rho激酶抑制剂。在β阻断剂方面，需要考虑的包括倍他洛尔、美替洛尔和噻吗洛尔；在前列腺素类似物方面，需要考虑的包括Bimatoprost、拉坦前列素、他氟前列素和曲伏前列素。这些区分至关重要，因为机制特异性的安全性和耐受性特征以及差异化潜力会影响临床定位和处方讨论。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 缓释性微针眼内植入在数月内持续控制眼内压的应用日益增加。
• 扩大微创青光眼手术与新一代药物传递系统的应用
• 开发并推出 Rho 激酶抑制剂，作为First-in-Class治疗药物
• 增加对旨在长期调控房水流出途径的基因治疗方法的投资
• 提高依从性可增加固定剂量Bimatoprost和奈他舒地尔复方组合药物的渗透率。
• 将家庭眼压监测与人工智慧演算法结合，实现个人化青光眼管理的数位健康平台正在涌现。
• 生技公司与眼科领域领导者加强策略伙伴关係，共同开发新型肽类疗法

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依药物类别分類的开放性青光眼药物市场

• α-促效剂
• β受体阻断剂
  • 倍他洛尔
  • 美替洛尔
  • 噻吗洛尔
• 碳酸酐酶抑制剂
• 固定剂量组合
• 前列腺素类似物
  • Bimatoprost
  • 拉坦前列素
  • 他氟前列素
  • 曲伏前列素
• Rho激酶抑制剂

第九章 依治疗类型开放性青光眼治疗市场

• 联合治疗
  • β受体阻断剂与摄护腺素
  • 碳酸酐酶抑制剂和β阻断剂
• 单药治疗

第十章 依给药途径分類的开放性青光眼药物市场

• 静脉
• 口服
• 局部的

第十一章 各地区开放性青光眼治疗市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十二章 按组别分類的开放性青光眼治疗市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十三章 各国开放性青光眼治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十四章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • AbbVie Inc.
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Aerie Pharmaceuticals, Inc.
  • Alcon Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.

The Open-Angle Glaucoma Therapeutics Market is projected to grow by USD 18.73 billion at a CAGR of 9.06% by 2032.

A concise and authoritative orientation to the evolving therapeutic landscape, unmet needs, and strategic imperatives shaping open-angle glaucoma care

Open-angle glaucoma remains a leading cause of irreversible vision loss worldwide, and therapeutics development continues to evolve in response to unmet clinical needs and technological progress. In recent years, the field has witnessed a shift from solely intraocular pressure-centric approaches to multidimensional strategies that consider neuroprotection, patient adherence, and combination regimens. This has broadened the evidence base that clinicians and payers evaluate when integrating new agents and delivery modalities into practice.

The introduction of novel mechanisms of action, advances in sustained-delivery systems, and an expanding emphasis on real-world outcomes have collectively reshaped clinical expectations and commercial models. Consequently, stakeholders across pharmaceutical, biotechnology, and medical device sectors are re-evaluating go-to-market plans, evidence-generation strategies, and partnerships. This introduction sets the stage for a focused exploration of the transformative shifts, regulatory and trade dynamics, segmentation nuances, regional considerations, and strategic actions that will define the therapeutic landscape in the near term.

How mechanistic innovation, advanced delivery technologies, and evolving payer expectations are fundamentally reshaping open-angle glaucoma therapeutic strategy and adoption

The therapeutic landscape for open-angle glaucoma is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces. Mechanistic innovation, particularly the emergence of Rho kinase inhibitors and other agents targeting trabecular outflow, challenges the long-standing dominance of traditional classes and invites head-to-head comparative effectiveness assessments. At the same time, improvements in drug formulation and delivery - including sustained-release implants and preservative-free topical options - are reshaping adherence patterns and clinical practice.

Concurrently, payer expectations and regulatory pathways are evolving, incentivizing robust real-world evidence and health-economic evaluations. Innovations in diagnostics, such as enhanced imaging and home-monitoring technologies, are enabling earlier detection and more individualized treatment adjustments. These combined trends are prompting a strategic realignment across life sciences companies and clinics: research and development pipelines are being prioritized for agents with demonstrable durability and tolerability advantages, commercial models are emphasizing patient support and adherence solutions, and partnerships between pharmaceutical and device manufacturers are becoming more common to deliver integrated care solutions.

Practical implications of tariff-driven supply chain shifts in 2025 and strategic responses that preserve access, continuity, and commercial momentum for therapeutics

The imposition of new tariffs in 2025 has introduced an additional layer of commercial complexity for therapeutics and devices that rely on globally sourced components and active pharmaceutical ingredients. Increased duties on imports can elevate the landed cost of raw materials and finished products, prompting procurement teams to reassess supplier portfolios and consider dual sourcing or regionalization strategies to preserve margin and supply continuity. In response, some manufacturers are accelerating nearshoring and contract manufacturing partnerships to mitigate exposure to tariff volatility.

Beyond direct cost impacts, tariffs influence strategic timelines and product launch sequencing. Companies may adjust supply chain footprints to prioritize markets with lower trade friction or to insulate critical production lines from tariff-related disruptions. This environment also amplifies the importance of contractual protections, such as long-term supply agreements and price adjustment clauses. From a clinical perspective, tariffs can indirectly affect access by increasing list prices or constraining the availability of certain imported formulations, thereby necessitating expanded patient assistance programs and adaptive reimbursement negotiations. Overall, the tariff landscape underscores the need for dynamic commercial strategies that integrate trade risk assessment, supply chain resilience, and proactive stakeholder engagement.

Segment-specific evidence priorities and commercialization levers drawn from drug classes, therapy types, and administration routes that shape therapeutic differentiation

A nuanced understanding of segmentation is essential to position assets and prioritize clinical and commercial investments across drug classes, therapy types, and routes of administration. Based on drug class, study considerations span Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors, Fixed Dose Combinations, Prostaglandin Analogues, and Rho Kinase Inhibitors, with the Beta Blockers category further disaggregated into Betaxolol, Metipranolol, and Timolol, and Prostaglandin Analogues examined across Bimatoprost, Latanoprost, Tafluprost, and Travoprost. These distinctions matter because mechanism-specific safety and tolerability profiles, as well as differentiation potential, influence clinical positioning and formulary discussions.

Based on therapy type, the market perspective encompasses Combination Therapy and Monotherapy, where Combination Therapy merits closer scrutiny for regimens such as Beta Blocker And Prostaglandin and Carbonic Anhydrase Inhibitor And Beta Blocker. Combination strategies often seek to improve intraocular pressure control while simplifying regimens to enhance adherence, which can materially affect real-world effectiveness. Based on route of administration, the clinical and commercial dialogue must address Intravenous, Oral, and Topical approaches, each of which carries unique considerations for delivery technology, patient acceptance, safety monitoring, and distribution logistics. Taken together, segmentation insights should drive targeted evidence generation and commercial differentiation for any candidate therapy.

How regional regulatory nuances, payer frameworks, and supply chain dynamics across the Americas, EMEA, and Asia-Pacific inform differentiated market entry and growth strategies

Regional dynamics materially influence regulatory pathways, reimbursement approaches, and commercial execution, requiring tailored strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, pricing negotiations, payer contracting, and patient support infrastructure are critical determinants of access and uptake, while clinical practice patterns and ophthalmology referral networks shape the adoption curve for new mechanisms and sustained-delivery systems.

In Europe, Middle East & Africa, diverse regulatory regimes and reimbursement criteria necessitate robust health-economic dossiers and region-specific real-world evidence. Market entry strategies must account for heterogeneous procurement processes and variable hospital purchasing practices across countries. In the Asia-Pacific region, regulatory modernization, growing biotech investment, and a rising focus on locally manufactured products create opportunities for collaboration and regional manufacturing. Across all geographies, supply chain resilience, local clinical data generation, and culturally attuned patient support programs are core enablers of sustained adoption and commercial success.

Competitive positioning and partnership models that enable durable differentiation across pharmaceutical, biotech, and device stakeholders in glaucoma therapeutics

Competitive dynamics in the open-angle glaucoma therapeutics space are shaped by a mix of large pharmaceutical companies, specialty biotechs, and device-focused manufacturers, each pursuing distinct routes to clinical and commercial differentiation. Established players typically leverage broad distribution networks, clinical trial experience, and payer relationships to support incremental innovations and lifecycle management. In contrast, smaller biotechs emphasize single-mechanism breakthroughs, nimble development timelines, and strategic partnerships to de-risk scale-up and access pathways.

Collaboration models are increasingly prevalent: co-development and licensing agreements bring together formulation expertise, delivery platforms, and commercialization capabilities. Meanwhile, device manufacturers that deliver sustained-release implants or novel administration systems are collaborating with drug developers to offer integrated solutions that address adherence and durability. Successful companies are those that align clinical development with pragmatic evidence generation, engage early with payers and key opinion leaders, and invest in patient-centric support services that reinforce real-world outcomes and reduce treatment discontinuation.

High-impact, actionable recommendations for R&D prioritization, commercial planning, and supply chain resilience to accelerate adoption and protect access

Industry leaders should pursue a coordinated strategy that aligns scientific differentiation with commercial execution and supply chain resilience. Prioritize development programs that address clear tolerability or adherence advantages over existing standards of care and design clinical trials to capture endpoints meaningful to clinicians, payers, and patients. This includes integrating quality-of-life measures and adherence metrics into pivotal studies and planning for real-world evidence generation from the outset.

From a commercial perspective, invest in patient support systems, clinician education, and value demonstration to build compelling reimbursement narratives. Strengthen supplier relationships and diversify manufacturing footprints to mitigate tariff and trade risks, and evaluate regional manufacturing or contract development and manufacturing organization partnerships where appropriate. Pursue strategic collaborations that combine delivery technology with pharmacologic innovation, and engage payers early to align on evidence requirements and pricing strategies. Finally, maintain adaptive launch sequencing and portfolio prioritization that reflects regional regulatory timelines, procurement environments, and local clinical practice patterns.

Transparent and reproducible research methods combining expert primary interviews and comprehensive secondary evidence to inform strategic decision-making

The report synthesizes primary and secondary research methods to create a robust, triangulated evidence base. Primary research included structured interviews with clinicians, payers, procurement specialists, and industry executives, complemented by advisory-board consultations and field-level insights from commercial teams. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to contextualize clinical development trends and market-access drivers.

Data from these sources were triangulated to reconcile differing perspectives and validate strategic conclusions. Quality-control measures included cross-validation of interview findings, reproducibility checks for analytical models, and a governance process for expert review. Where gaps existed, targeted follow-up interviews were conducted to ensure the analysis reflected current practice and regulatory dynamics. The methodology emphasizes transparency and reproducibility while prioritizing practical insights that inform clinical development, commercialization, and policy strategy.

A conclusive synthesis of therapeutic innovation, evidence priorities, and operational imperatives that leaders must address to translate advances into sustained clinical and commercial success

In summary, the open-angle glaucoma therapeutics landscape is entering a phase where mechanistic innovation, delivery advances, and evolving payer expectations converge to create both opportunity and complexity. Companies that integrate differentiated clinical value with durable delivery solutions and robust real-world evidence will be best positioned to influence clinical practice and secure reimbursement. Simultaneously, trade dynamics and regional heterogeneity require proactive supply chain planning and localized market strategies.

Achieving sustained impact will depend on aligning R&D priorities with pragmatic evidence generation, engaging stakeholders across the care pathway early, and deploying patient-centric commercial programs that support adherence and long-term outcomes. Decision-makers who adopt an integrated approach-combining scientific differentiation, commercial rigor, and operational resilience-will be able to translate therapeutic innovation into improved patient care and durable business performance.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rising adoption of sustained-release microneedle ocular implants for continuous IOP control over months
• 5.2. Expanding usage of minimally invasive glaucoma surgery combined with next generation drug delivery systems
• 5.3. Development and commercial launch of Rho kinase inhibitors as first-in-class therapy targeting trabecular meshwork
• 5.4. Growing investment in gene therapy approaches for long-term modulation of aqueous humor outflow pathways
• 5.5. Increasing penetration of fixed-dose bimatoprost and netarsudil combinations driven by adherence benefits
• 5.6. Emergence of digital health platforms integrating home tonometry and AI algorithms for personalized glaucoma management
• 5.7. Escalating strategic partnerships between biotech firms and ophthalmology leaders for novel peptide therapeutics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Open-Angle Glaucoma Therapeutics Market, by Drug Class

• 8.1. Alpha Agonists
• 8.2. Beta Blockers
  • 8.2.1. Betaxolol
  • 8.2.2. Metipranolol
  • 8.2.3. Timolol
• 8.3. Carbonic Anhydrase Inhibitors
• 8.4. Fixed Dose Combinations
• 8.5. Prostaglandin Analogues
  • 8.5.1. Bimatoprost
  • 8.5.2. Latanoprost
  • 8.5.3. Tafluprost
  • 8.5.4. Travoprost
• 8.6. Rho Kinase Inhibitors

9. Open-Angle Glaucoma Therapeutics Market, by Therapy Type

• 9.1. Combination Therapy
  • 9.1.1. Beta Blocker And Prostaglandin
  • 9.1.2. Carbonic Anhydrase Inhibitor And Beta Blocker
• 9.2. Monotherapy

10. Open-Angle Glaucoma Therapeutics Market, by Route Of Administration

• 10.1. Intravenous
• 10.2. Oral
• 10.3. Topical

11. Open-Angle Glaucoma Therapeutics Market, by Region

• 11.1. Americas
  • 11.1.1. North America
  • 11.1.2. Latin America
• 11.2. Europe, Middle East & Africa
  • 11.2.1. Europe
  • 11.2.2. Middle East
  • 11.2.3. Africa
• 11.3. Asia-Pacific

12. Open-Angle Glaucoma Therapeutics Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Open-Angle Glaucoma Therapeutics Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Analysis
  • 14.3.1. AbbVie Inc.
  • 14.3.2. Novartis AG
  • 14.3.3. Pfizer Inc.
  • 14.3.4. Merck & Co., Inc.
  • 14.3.5. Santen Pharmaceutical Co., Ltd.
  • 14.3.6. Aerie Pharmaceuticals, Inc.
  • 14.3.7. Alcon Inc.
  • 14.3.8. Viatris Inc.
  • 14.3.9. Teva Pharmaceutical Industries Ltd.
  • 14.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 9. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 140. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 141. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 142. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 143. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 144. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 145. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 146. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 147. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 153. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 156. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 157. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 158. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 159. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 160. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 161. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 162. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 163. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 164. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 165. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 166. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 167. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 170. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 171. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 172. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 173. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 174. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 175. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 176. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 177. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 178. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 179. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 180. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 181. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 182. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 183. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 184. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 185. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 186. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 187. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 188. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 189. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 190. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 195. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 197. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 209. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 212. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 213. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 214. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 215. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 216. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 217. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 218. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 219. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 220. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 221. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 222. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 223. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 226. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 227. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 228. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 229. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 230. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 231. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 232. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 233. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 234. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 235. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 236. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 237. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 240. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 241. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 242. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 243. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 244. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 245. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 246. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 247. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 248. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 249. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 250. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 253. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 256. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 257. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 258. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 259. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 260. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 261. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 262. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 263. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 264. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 265. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 266. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 267. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 268. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 269. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 270. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 271. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 272. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
• TABLE 273. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
• TABLE 274. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
• TABLE 275. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 276. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 277. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
• TABLE 278. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
• TABLE 279. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 280. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 281. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 282. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 283. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 284. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 285. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
• TABLE 286. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD